Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158

Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158

  • Cambridge, Mass., July 13, 2021 – Artax Biopharma, Inc., a biotechnology company focused on transforming the treatment of T Cell-mediated diseases, today announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted clinical trial authorization to evaluate AX-158 in a Phase 1 clinical trial for the treatment of T Cell-Mediated Diseases.

Read more